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Abstract 
Introduction: Neoplasia is defined as abnormal and excessive growth of selected tissue. 
Several factors, such as mutations in selected genes, can increase the risk of cancer 
expansion in human body. The aim of the article is to review the selected genetic factors 
which increase the risk of neoplasia and results of their presence in the human body. 
Material and methods: Articles in the Google Scholar, Pub Med database have been 
analysed using keywords: cancer, neoplasia, genetic factors, driver genes, cancer 
transformation, older people. 
Results: The aim of several genes is repairing damaged or dysfunctional DNA and 
preventing cells from abnormal or excessive. Mutations in selected genes cause inhibited 
production of the gene protein product or a change in its function, which increase the risk of 
neoplasia. The presence of mutated genes results in the initiation of the process leading to 
expansion of cancer cells in selected tissue. Moreover, a genetic mutation can lead to 
syndrome of tumors occurring in several organs. However, the increasement of cancer risk 
is related to numerous mutations, whereas the minority of carcinomas occur because of 
congenital gene defect and the majority is caused by environmental factors which contribute 
to creating various mutations. 
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Conclusions: Thanks to the development of genetics in the field of medicine and 
introduction of genetic tests, the process of diagnosis of several tumors and syndromes is 
more efficient than in the past. The occurrence of mutation in genes, such as BRCA1, 
BRCA2, VHL, MSH2 and MLH1 and many more, relates to presence of selected tumors. 
By the introduction of pharmacogenetics, dozens of molecular-targeted drugs are used in the 
treatment of several types of cancers leading the achievement of therapeutic success.  
Nevertheless, the genetic background of many types of cancers is unknown and needs 
further study, as well as drugs targeting at selected genes mutations requires more 
development and guidelines in the treatment process. 
 
Keywords: cancer; neoplasia; genetic factors; driver genes; cancer transformation; older 
people; 
 
Introduction: 
Cancer is a generic term for a large group of diseases characterized by the growth of 
abnormal cells beyond their usual boundaries that can then invade adjoining parts of the 
body and/or spread to other organs. Other common terms used are malignant tumours and 
neoplasms. Cancer can affect almost any part of the body and has many anatomic and 
molecular subtypes that each require specific management strategies. 
Cancer is the second leading cause of death globally and is estimated to account for 
9.6 million death in 2018. Lung, prostate, colorectal, stomach and liver cancer are the most 
common types of cancer in men, while breast, colorectal, lung, cervix and thyroid cancer are 
the most common among women [1]. 
 Cancer arises from the transformation of normal cells into tumour cells in a 
multistage process that generally progresses from a precancerous lesion to a malignant 
tumour. These changes are the result of the interaction between a person's genetic factors 
and 3 categories of external agents, including: 
 Physical carcinogens, such as ultraviolet and ionizing radiation; 
   
 Chemical carcinogens, such as asbestos, components of tobacco smoke, aflatoxin (a 
food contaminant), and arsenic (a drinking water  contaminant); and 
   
 Biological carcinogens, such as infections from certain viruses, bacteria, or parasites 
[3]. 
A mutation is a change in a genetic sequence. Mutations include changes as small as 
the substitution of a single DNA building block, or nucleotide base, with another nucleotide 
base. Meanwhile, larger mutations can affect many genes on a chromosome. Along with 
substitutions, mutations can also be caused by insertions, deletions, or duplications of DNA 
sequences. 
Some mutations are hereditary because they are passed down to an offspring from a 
parent carrying a mutation through the germ line, meaning through an egg or sperm cell 
carrying the mutation. There are also non hereditary mutations that occur in cells outside of 
the germ line, which are called somatic mutations. Mutations can be introduced due to 
mistakes made during DNA replication or due to exposure to mutagens, which are chemical 
and environmental agents that can introduce mutations in the DNA sequence, such as 
ultraviolet light. Some mutations do not result in changes in the amino acid sequence of the 
encoded protein and can be described as silent mutations. Other mutations result in 
abnormal protein products. Mutations can introduce new alleles into a population of 
organisms and increase the population's genetic variation [2]. 
Cancer is caused by two general factors: 
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1. Internal factors such as inherited mutations, hormones, and immune conditions 
   
2. External/environment/acquired factors such as tobacco, diet, radiation and infectious 
organisms 
All cancers are a result of multiple mutations. Only 5–10% of all cancers are due to an 
inherited gene defect. 90-95 % of cancers is arised from environmental factors, but all of 
environmental factors cause the acquisition of cell mutations [4]. 
Cancer is a typical example of a multigenic disease, which means that the cause of 
cancer is simultaneous damage in many genes. Synchronous damage to many of the 
processes carried out by the cell leads to the loss of homeostasis. Transforming a healthy 
cell into a cancer cell requires the appearance of several to several dozen genetic damage at 
one time. In addition, genetic damage must refer to the so-called driver genes, only changes 
in this group of genes are able to change the healthy cell into a cancer cell. We can not 
forget about passenger genes that affect the tumor phenotype, but independent gene damage 
from this group is not able to initiate the process of carcinogenesis. The driver genes is 
relatively small, in different types of tumors their role may have a different meaning, that is, 
the driver genes in one type of cancer are driver genes and in others are passenger genes. 
Similarly, the case looks like passenger genes. An interesting phenomenon is the diversified 
ability to induce the process of tumorigenesis of the same driver genes, for example 
mutations in BRCA1 are a stronger activator of carcinogenesis in breast cancer than in 
ovarian cancer or prostate cancer. Unfortunately, we can not choose the genome we inherit 
but for this we can identify genetic changes in our genome that increase the probability of 
cancer transformation. 
Searching for causes of familial occurrence of a specific type of cancer has led to the 
separation of a group of genes called susceptibility genes, the occurrence of mutations in 
these genes increases the risk of developing a specific type of cancer. Susceptibility genes, 
depending on how much they increase the probability of falling ill, are divided into: 
 Genes  with high penetration 
   
 Genes  with average penetration 
   
 Genes  with low penetration 
Genes with high penetration increase the risk of getting close to unity, and genes 
with average penetration several times. Genes belonging to these two groups belong to the 
driver genes but their involvement in cancer transformation is of secondary importance, 
because the most important cause of carcinogenesis is lifestyle. Low penetration genes are 
usually polymorphic variants of detoxification genes, for example NOD or GST. Most 
susceptibility genes are suppressor genes, their damage leads to uprising defective products 
that interfere with cell homestasis by affecting DNA repair mechanisms, cell cycle 
regulation, differentiation or apoptosis. Not many susceptibility genes are proto-oncogenes, 
their damage increases the risk of cancer development, because they are activating 
mutations that directly or indirectly affect the signal transmission in the cell.  
 The implementation of a subpopulation of healthy people, in whom genetic and 
molecular studies have detected genes that increase the risk of cancer for medical 
surveillance would increase the effectiveness of screening tests and clearly reduce the cost 
of medical care. Treatment of neoplastic diseases should be strengthened by molecular 
examination of the disease in order to maximize the personalization of the treatment - 
treatment to the molecular subtype of the disease and treatment taking into account 
individual variability in the metabolism of drugs - pharmacogenomics [5]. 
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BRCA1 and BRCA2 genes 
BRCA1 is a human gene encoding protein called BRCA1 (Breast cancer type 1 
susceptibility protein). Location of this gene is on the long arm of chromosome 17 (17q21) 
[6]. Length is 81097 base pairs and contains 24 exons[7,8]. 
Product of BRCA1 gene expression is protein, as mentioned before, called BRCA1 
(the same as the gene) consisting of 1873 amino acids residues [6]. 
There are four major domain in this protein: Znf C3HC4- RING domain at the N-
terminal region, the BRCA1 serine domain, two BRCT at the C-terminal region. BRCA1 
protein is expressed in mainly breast cells (and other tissues) and is responsible for repairing 
damaged DNA and causing apoptosis of a cell if damage cannot be repaired [9]. 
BRCA1 protein plays an important role in repairing double-strand breaks (DSBs) in 
DNA. It is a part of protein complex responsible for fixing DNA when double-strands are 
broken. It is difficult to replace broken parts of DNA when both of strands are damage since 
there is no matrix strand that this protein complex can use to copy and repair with base 
complementary rule. Therefore BRCA1 protein assist homology-directed repair 
(homologous recombination - HR) which copy a sequence from intact sister chromatid. In 
this process in the nucleus BRCA1 protein binds with RAD51 protein during the repair [10]. 
 BRCA1 protein also participates in activation of cell cycle checkpoints. Cell 
cycle checkpoints are used to supervise the chromatin status during cell cycle. If there is 
damage in the DNA, then cell cycle checkpoints are activated and prevents cell from 
proceeding to replicate. That gives time for protein repair complexes to fix damages in DNA 
before duplication of DNA [11]. 
BRCA2 gene is located on chromosome 13 in positions 12.3 on the long arm (q) - 
(13q12.3). It contains 27 exons. Length is 84 792 base pairs [13]. 
BRCA2 gene encodes protein BRCA2 (Breast cancer susceptibility protein 2) 
formed by 3 418 amino acids. Similar to BRCA1 protein, BRCA2 protein expression occur 
mainly in breast cells (but in other cells as well) and also participates in forming genomic 
stability and help fixing DNA damage [14]. 
As mentioned before, despite different origin and structure of BRCA2 and BRCA1 
protein, they function in similar manner, both binds to RAD51 protein and plays a role in 
homologous recombination. The BRCA2 protein is key part of HR. When it binds to 
RAD51 protein it enhance recombinational DNA repair by promoting congregation of 
RAD51 onto single-stranded DNA [15]. Its is worth to mention that in order to assembly 
RAD51 to DNA DSBs a formation of BRCA1-PALB2-BRCA1 complex is required [16]. 
Mutations in either of mentioned genes lead to increased risk of breast and ovarian 
cancer and may produce hereditary breast-ovarian cancer syndrome (HBOCS). There are 
hundreds of types of mutations that have been detected in those genes, some are harmful, 
while others have no proven impact. There are also possibility of single nucleotide 
polymorphism which may higher risk of cancer by a small amount or only in certain 
circumstances [17]. 
Estimated 12% of women in overall population will develop breast cancer in their 
lives. On the contrary, 72 % of women with BRCA1 and 69% of women with BRCA2 
mutation will have breast cancer by the age of 80. Similar tendencies are visible in ovarian 
cancer with 44% of women with BRCA1 mutation developing ovarian cancer and 17% with 
BRCA2, in contrast to 1.3 % women having an ovarian cancer in overall population at some 
point in their lives [18]. 
 There is no surprise why those number are that high. High-risk mutations disable 
proper function of BRCA1 and BRCA2 genes that leaves cells with damaged DNA without 
possibility to repair that cause them to be prone to develop cancer. 
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 Interestingly some populations are more susceptible to cancerogenesis than others. 
This has to do with founder effect. This effect occur when a population is established with 
small number of individuals and that cause certain genetic traits to prevail in population, 
there BRCA1 and BRCA2 gene mutations [19]. The proven groups with higher prevalence 
of harmful mutations are for example Ashkenazi Jews or when it comes to Europeans, in 
Norwegians, Danes or Icelanders [18]. 
We know from the description of function above what role BRCA1 and BRCA2 
proteins play in cells, thus we may predict and observe what effects on cells will have 
mutations that impair functions of those proteins. 
Mutated cell will be unable to perform error-free repair process - homology directed 
repair, therefore cell is left with genetic disorder that may lead to breast or other types of 
cancer. Furthermore activation of cell cycle checkpoints will be impaired which might cause 
that previously damaged DNA will be conveyed to child cells and that increases chances of 
cancerogenesis as well, but it seems it is only an issue in cells with BRCA1 gene mutations, 
because BRCA2 protein doesn’t have clear effect on cell cycle checkpoint enforcement. In 
addition there can be problems with modulation of chromatin and DNA structure in mutated 
cells which probably could have a negative effect on accessibility of DNA changes to repair 
mechanisms, but more research has to be conducted on this subject. 
At the end it has to be acknowledged that those difunctions are mainly in BRCA1-
deficient cells, because despite involvement of BRCA2 protein in repairing damaged cell 
DNA is certain, the functions of BRCA2 protein is not as marked as those of BRCA1 
protein, and yet more research is necessary [20]. 
 
VHL gene 
 VHL gene is located on the short arm of chromosome 3 (3p25.3) and include 4 
exons. Exact location starts at 10141635 and ends at 10153670 bp from pter [21,22,23,24]. 
The highest expression is in lymph node and spleen. It also appear in brain,, kidney, lung 
and many more organs[25]. 
 VHL encode two isoform of protein: pVHL30 (30 kDa and 213 amino-acid), 
pVHL19 (19 kDa and 160 amino-acid). There is currently 761 different types of VHL 
described mutation [26]. Both gene products have tumor suppressor activity in vivo [27]. 
Protein VHL is aggregating with elongin C and elongin B to form VCB complex. It then 
incorporate cullin 2 (CUL 2) and the RING finger protein RBX1 creating more complex 
structure called VCB-CR complex, which is in charge of ubiquitylation and proteasomal 
degradation of HIF1α (hypoxia-inducible factor 1α) in normoxia [28]. HIF1α together with 
HIF1β bind to enhancer called a hypoxia response element that appear in many genes 
activated while oxygen deficiency such as VEGF ,glycolytic enzymes, erythropoietin. 
 Absence or inappropriate function of pVHL in VCB-CR complex causes 
angiogenesis, erythropoiesis and greater contribution in anaerobic metabolism, by not 
forming complex which degrades HIF1α [29]. Furthermore pVHL most likely play a role in 
other cellular functions such as microtubule stabilization, maintenance of the primary 
cilium, regulation of apoptosis, controlling of cell senses, degradation of TGFα, LYT 10, 
TGF β, carbonic anhydrases CA9 and CA12.Products of VHL gene also allow cell to exit 
cell cycle and enter the quiescent state and inhibit hepatocyte growth factor (HGF), which 
overexpressed can lead to invasion in renal cell carcinoma [24]. Mutation in VHL can also 
cause increase production of TGFα, which act to stimulate growth of cell within the tumor 
[30]. Based on this roles VHL is classified as tumor suppressor [31]. 
 Identification of pVHL role in regulating HIF- mediated cellular resonse to hypoxia, 
influence today’s ccRCC treatment. There are drugs which include multiple tyrosine kinase 
inhibitors that target VEGF receptors (sorafenib, pazopanib), inhibitor of the mTOR 
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pathway- responsible for cell proliferation (temsirolimus, everolimus) and the monoclonal 
anti-VEGF antibodies (bevacizumab) [32]. So far there aren’t any studies which 
unequivocally states that the presence or absence of mutation might provide useful 
biomarker in ccRCC. However it is caused by insufficient number of studies because 
effective treatment options have come into widespread use only recent. 
 
MSH2 gene 
MSH2 is a tumor suppressor gene that encodes post-replication DNA mismatch 
repair protein called MSH2. It is characterized by two locations, i.e. cytogenetic and 
molecular [33]. These two types of localization boil down to one description indicating the 
area from 47 403 067 to 47 634 501 base pairs (bp) located on the short arm of chromosome 
2 between 21 and 16.3 positions (2p21-p16.3)[33,34,35,36]. It is yeast mutator gene 
homolog (bacterial mutS). The MSH2 gene contains 16 exons that cover the area of 80098 
bp. The length of mRNA characteristic for the MSH2 gene is 3145 bp. The described gene 
has two characterized transcription variants (1 and 2 variants) coding for different isoforms 
that differ in length [37]. This is due to the lack of the first exon that has a place to start 
translation, so the first transcript is shorter than the N-terminal side. MSH2 is characterized 
by nuclear expression. In addition to participating in DNA repair, MSH2 and products 
encoded by this gene are involved in: oxidative phosphorylation, embryonic development of 
utero and somatic recombination of immunoglobulin genes. Expression of MSH2 is 
characterized by tissue specificity observed primarily for: colon, lymph node, testis, thyroid, 
bone and fetal ovary [36,37]. Overexpression of described gene is also observed in 
peripheral blood mononuclear cells, melanocytes and CD8 T cells [36]. For example, the 
expression of this gene in monocytes can causa UV-B-induced cell cycle regulation but also 
apoptosis [36]. 
The MSH2 also referred to as the MutS 2 protein homolog is a protein consisting of 
934 amino acids. The molecular weight is 104.7 kilodaltons (kDa) [36]. MSH2 contains two 
interaction domains and one DNA binding domain, for MSH3 or MSH6 and for MutL 
homologs. The presence of these domains enables the formation of heterodimeric 
complexes. The MSH2 protein forms two different heterodimers: MutS alpha (MSH2-
MSH6) and MutS beta (MSH2-MSH3) (MutS beta). MutS alpha recognizes base-base 
dinucleotide insertion-deletion loops (IDL) and single base mismatches in a strand of DNA 
while MutS beta recognizes large insertion-deletion loops up [36,38,39]. MutS alpha and 
MutS beta forms a ternary complex with MutL which is responsible for strand recognition, 
excision, and resynthesis [39].  
MSH2 and complexes which it forms are primarily responsible for binding DNA 
mismatches, which initiates the process of genetic material repair. Described mechanism 
named post-replicative DNA mismatch repair (MMR). It is necessary system to combat 
genomic damage.          
MSH2 is also responsible for recruits DNA helicase MCM9 to chromatin. This 
causes unwinds of DNA stand which contains DNA mismatch. It comes to then ATP 
binding and hydrolysis which is necessary in MMR. The most important moment for MutS 
2 protein during the whole MMR process is converts MSH2 for a sliding clamp which 
allows diffusion and repair along the DNA backbone. This is essentials for the initiation and 
operation of the MMR system [39,40,41]. MutS protein homolog 2 also has many functions 
specific to the MSH2 gene. As previously mentioned these are oxidative phosphorylation, 
embryonic development of utero and somatic recombination of immunoglobulin genes but 
also magnesium ion binding [36]. MSH2 also interacts with various types of proteins 
[39,40]. The MSH2 protein is part of the MutS family which includes also MSH 1, 3, 4, 5 
and 6 proteins. Their expression is observed in eukaryotes but also among archaea and 
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bacteria [41]. 
Mutations within the MSH2 gene are most often associated with microsatellite 
instability. These are short sequence repeats which occurs because these sequences are 
prone to mistakes during the DNA replication [42]. If the repair systems do not work, 
duplications or deletions of these sequences arise over time. Excessive accumulation of 
DNA damage and lack of activity of the MMR system result increasing the quantity of 
mutations due to error-prone translesion synthesis .This results in more frequent DNA 
damage and may be responsible for the occurrence of various diseases, among which cancer 
takes the first place [42,43,44].  
Within MSH2 is described over 300 germline mutations. These are not occur in any 
specific region of the gene and include both insertions/deletions as also nucleotide 
substitutions (nonsense, missense and splicing errors) [43,44,45]. 
Most mutations result in the occurrence of tumors, i.e. hereditary non-polyposis 
colorectal cancer 1 (HNPCC1), acute lymphoblastoid leukemia (ALL), endometrial cancer, 
mismatch repair cancer syndrome (MMRCS), colorectal cancer (CRC), ovaria cancer, renal 
cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous-cell 
carcinoma, hepatocellular carcinoma, gastrin cancer and soft-tissue sarcoma. Many of the 
diseases listed are also caused by MSH2 promoter methylation [33,34]. 
Mutations within MSH2 can also cause Lynche syndrome and its wariant - Muir-
Torre syndrome but also non-neoplastic diseases such as Takayasu arteritis, chronic kidney 
disease and Alzheimer's disease [46]. Most mutations within MSH2 cause the above-
mentioned disease entities, however described some genetic changes have also been in 
exons and introns as non pathogenic for organism [46].  
The most common condition associated with the mutation within MSH2 is 
HNPCC1. It is a disease of an autosomal dominant character. The most characteristic for 
this disease is Replication ERror phenotype (RER+). Presence of mutations in the MSH2 
gene resulting in HNPCC1 is characterized by predisposition to early-onset extra-colonic 
tumors of the gastrointestinal, colorectal carcinoma and cancer both urological as also 
female reproductive tracts. HNPCC is divided into two subgroups. Type 1 is associated 
primarily with predisposition to proximal colon cancer. While type 2 is responsible for 
increased risk for many types of cancers within uterus, breast, ovary, stomach, skin and 
small intestine. Mutations of MSH2 contributing to HNPCC account for about 25% of all 
examples of genetic material abnormalities in this area. These mutations are germline 
Mutation occurs in one of the alleles and the loss of heterozygosity (LOH) gives the 
mutations causing HNPCC1 a dominant character. More over HNPCC1 can be caused by 
MicroSatellite Instability (MSI) [46,47,48]. In most cases, MSH2 related diseases are 
caused by different types of mutations. However, also reduction of MSH2 expression can 
lead to cancer such as non-small cell lung cancer (NSCLC) [46,47,49]. 
 
MLH1 gene 
MLH1 is a tumor suppressor gene which is responsible for coding the protein 
playing a major role in DNA repair. The cytogenetic location of MLH1 gene is short arm of 
chromosome 3, in band 22 counting from the centromere, in sub-band 2. It was determined 
with fluorescence in situ hybridization [55]. This gene is located between 36.993,350 and 
37.050.846 base pairs [50]. 
MLH1 is one of the genes responsible for mismatch repair (MMR). The human 
MLH1 gene is a homologue of the E. coli MutL gene specially in the N-terminal region. 
Orthologs MLH1 is observed among 274 organisms highlighting e.g. mouse and yeast 
Saccharomyces cerevisiae. MLH1 takes part in protein-protein interactions during the 
differentiation of DNA strands and their removal. Also participates in recognizing non-
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compliance with nitrogen bases. This gene encodes a protein of the same name, or MLH1, 
which has 9 isoforms. Most of them perform similar functions to the transcription variants 
corresponding to the MSH2 isoforms. The differences are based on lack of one of the exons 
in option 6, which leads to frameshift. or presence of ATP-binding proteins such as histidine 
kinase, topoisomerases, heat shock protein HSP90, DNA gyrase B, phytochrome-like 
ATPases and DNA mismatch repair proteins [51,52]. MLH1 includes 19 exons located in 
the area of 57360 bp, which answers approximately 100kb. Additionally, exons 1 to 7 have 
a region that is highly conserved in the MLH1 and PMS1 genes of yeast [55] .The length of 
the gene is in the area from 6993350 and ends at 37050846 bp. Moreover, length of 
transcribed mRNA for this gene is 2524 bp [53]. Overexpression of described gene is 
observed in colon, breast, lung, lymphocytes, spleen, prostate, thyroid, testis, gallbladder 
and heart [54]. 
The MLH1 also known as MutL homolog 1 is a protein whose molecular mass is 
84.6 kDa. This protein contains 756 aminoacids [53]. The MLH1 gene contains an ATPase 
(Adenosine triphosphate) domain but also two domains whose heterodimerize with MutS 
homologs (MSH2, MSH3, MSH6) and MLH3, PMS1 or PMS2. 
After binding with PMS2 a heterodimer MutLα is formed. It is responsible for the 
recruitment of the proteins whose are needed for the excision and repair synthesis. MLH1 is 
a protein that has no catalytic properties [53]. MutLα can interact with MutSβ. Then, the 
PMS2 subunit present in the complex formed breaks the single strand of DNA near the 
DNA mismatches, which provides a starting point for exonuclease degradation. MutLα can 
also heterodimerize with MLH3. A complex called MutLγ is created then which involved in 
meiotic crossing over.[51]. MutLγ heterodimer is necessary for the passage of oocytes 
through metaphase II of meiosis [56]. 
Based on the above information, can be distinguish several groups of proteins with 
which MLH1 interacts. Expression of MLH1 is presents for 27 different tissues but 
overexpress is observed in testis, thyroid, lymph node and heart. ) At the cellular level, high 
activity is observed within the cell nucleus (in particular in chromosomes) [52].  
MLH1 is part of the BRCA1-associated genome surveillance complex (BASC) and 
RAD50-MRE11-NBS1 protein complex. MLH1 protein interacts with subunits of DNA 
polymerase III. It plays an important role to recruit the DNA polymerase III for the site of 
the MMR. MLH1 engages in signaling damage to the genetic material, which results in the 
arrest of the cell cycle and the induction of apoptosis in case of major DNA damages [52]. 
The activity of MLH1 protein is also observed in chromatin binding, guanine/thymine 
mispair binding, isotype switching, meiotic spindle midzone assembly, meiotic telomere 
clustering, response to bacterium, somatic hypermutation of immunoglobulin genes, 
spermatogenesis and synapsis activity [54]. 
Mutations in the MLH1 gene result from microsatellite instability. Their formation 
leads to inhibited production of the MLH1 gene protein product or a change in its function. 
The effect of this is the increase and accumulation of errors in the DNA created during cell 
division, which leads to malfunctions of the cell leading to neoplastic transformation. 
Mutations in the MutL gene mainly occurring in the ATP-binding site because MutL is 
responsibles for bind and hydrolyzes ATP to ADP and Pi [55][62]. 
Mutations occurring within MLH1 are in the form of nucleotide substitutions 
(nonsense, missense, splicing errors) and insertions/deletions. The MLH1 protein resulting 
from the mutation has the most abbreviated structure [53].  
The result of mutations is mostly hereditary non-polar colorectal cancer (HNPCC), 
also referred to as Lynch syndrome. It is a dominant autosomal disease associated with an 
increased risk of colon cancer. It arises due to the excision of 16 or 6 exons. About 50% of 
all cases of Lynch syndrome are associated with hereditary mutations in the MLH1 gene. 
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Lynch syndrome is associated not only with colon cancer, but also with an increased risk of 
ovarian cancer, endometrial cancer, liver, small intestine, gallbladder, brain and upper 
urinary tract [62].  
It is important to reduce the expression or silencing of DNA repair genes resulting 
from the methylation of the MLH1 gene promoter region and miR-155 overexpression. This 
may result in stomach cancer, esophageal, Head and neck squamous cell carcinoma 
(HNSCC), Non-small cell lung cancer (NSCLC) or colorectal cancer. Disorders within the 
MLH1 gene can also contribute to the occurrence Turcot syndrome which is associated with 
an increased risk of glioblastoma occurrence [62]. 
 
Discussion  
The development of genetics, which resulted in the recognition of the human genome and its 
various variations - mutations and polymorphisms, contributed to the discovery of the 
causes of many genetic diseases. The development of this branch of science has also 
allowed the discovery of predictors and prognostic factors of various diseases. 
 Thanks to the development of pharmacogenetics, dozens of molecular-targeted drugs 
are created every year, and a large part of them is used in the treatment of cancer. Most 
often, cancerous mutations are associated with excessive activity of proteins formed from 
mutated genes. This results in a disruption of the signaling pathways and this disturbs the 
homeostasis of the cell. In this case, blocking the mutant signaling pathway causes 
suppression of tumor cells. Many tumors show heterogeneity which prompts you to look for 
new drugs. 
 Thanks to genetic tests, it is possible to detect both mutations conditioning 
sensitivity to targeted therapies and detection of resistant cells for this type of treatment. 
Without genetic testing, it is not possible to qualify patients for molecular-targeted therapy 
[63]. 
 Genetic testing is also used to detect mutations that cause non-cancer diseases such 
as hemochromatosis, Crohn's disease, etc., but genetic tests in oncology are the most useful 
and used on the largest scale. According to the recommendations of the global oncology 
societies, the most common mutations in oncology should be determined in common 
clinical practice [64]. 
 Currently, apart from the classic histopathological classification of tumors, more and 
more cancers also receive molecular classifications. About 20 molecular markers are 
currently accepted by the European Society for Medical Oncology for gastric, prostate, 
breast, lung and colorectal cancer as properly documented so that they can be used in 
clinical practice. 
 Personalized treatment is now directed towards the driver genes. In this way, 
molecular diagnostics has been included in the diagnostic part of cancer [65]. 
 The statement of a mutation can have a significant impact on the course of the 
disease, and thus the fate of the patient and his family. Errors and lack of standardization of 
genetic tests can have disastrous consequences. Therefore, conducting genetic research 
requires strict legal regulations. In the European Union, regulations are set by individual 
countries. In the European Union there is a EuroGentest institution financed by the 
European Union, which deals with the design of legal regulations and the control of tests 
available in Europe. In Poland, the law regulating the legal issues of genetic testing has not 
been adopted so far [64]. 
 In Poland, it is difficult to talk about the development of modern personalized 
medicine in oncology due to the lack of legal regulations for genetic testing, lack of genetic 
and oncological diagnostic infrastructure, lack of detailed standards of genetic testing and 
lack of appropriate funds for diagnostics by the National Health Fund. Lack of expenditure 
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on laboratories operating within the national health care system may lead to the inhibition of 
activities and the development of laboratories. 
 Lack of state supervision and quality control of genetic diagnostics provokes clients 
(hospitals, oncology clinics) to use cheaper services performed by laboratories, not subject 
to any supervision, or send patients' DNA abroad [65]. 
 However, the development of genetics-related branches of science significantly 
increases the possibilities of personalized treatment of cancer. However, this development 
creates new challenges. Such as developing standardized genetic tests, performing tests in 
laboratories equipped with appropriate diagnostic equipment. In addition, steps should be 
taken to establish a transparent system for the control of genetic laboratories and the 
validation of methods used by them, as well as a good system for financing genetic testing. 
A permanent update of test recommendations and genetic laboratories is required based on 
the latest guidelines [63]. 
 
Conclusions  
Cancers are huge problem for global public health and one of the leading causes of 
deaths especially in highly developed countries where we observe an increase in life 
expectancy. There are multiple factors causing carcinomas – they may be divided into three 
groups: physical, chemical and biological. We also distinguish the simplest division into 
internal (for example inherited mutations, endocrine disruptors) or external causes 
(radiation, diet, lifestyle etc.). In this work selected genetic factors increasing risk of 
neoplasia were described. It is worth to mention that all cancers are a consequence of 
numerous mutations, however minority of carcinomas occur because of congenital gene 
defect. Significant majority of cancers is caused by environmental factors which contribute 
to creating various mutations. 
 First of all, BRCA1 and BRCA2 were described. Function of these proteins is 
similar, however they are not related. They were mentioned together because they are both 
associated with higher risk of breast cancer. Furthermore, mutations of BRCA1 and BRCA2 
genes are connected also with developing ovarian cancer. Mentioned mutations appear more 
often in certain populations like Ashkenazi Jews or Scandinavians like Icelanders, Danes or 
Norwegians. 
 Next, VHL gene mutation was outlined in a similar way to two previous mutations. 
This gene plays a part in many cellular activities like regulation of apoptosis or microtubule 
stabilization. It is worth noting that it is classified as a tumor suppressor, because it 
enhances the degradation TGF alpha, nevertheless mutations in this gene stimulate growth 
of neoplastic cells inside the tumors. Renal cell carcinoma is associated with VHL gene 
mutation. 
 MSH2 gene mutations are mainly connected with microsatellite instability which 
leads to many diseases and cancer is the most common one. Results of this mutation are for 
example hereditary non-polyposis colorectal cancer 1, acute lymphoblastic leukemia, 
endometrial cancer and soft-tissue sarcoma. Besides tumors mutations of described gene can 
also cause vascular diseases like Takayasu arteritis or neurodegenerative one - Alzheimer’s 
disease. 
 Last but not least, MLH1 gene is also tumor suppressor like VHL outlined earlier. At 
the cellular level its mutations lead to microsatellite instability what also was mentioned in 
the description of MSH2 gene. It is also connected with 50% of cases of Lynch syndrome 
(which is also caused by mutations of MSH2 gene), which causes increased risk of colon 
cancer. However in this syndrome, there may appear tumors in different organs for example: 
ovary, gallbladder or brain. Furthermore, its mutations also may lead to non-small cell lung 
carcinoma, stomach cancer or colorectal cancer. 
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 To conclude, genetic factors increasing risk of neoplasia are scientifically and 
medically very important subject. Thanks to the development of different branches of 
biomedical sciences we know much more about neoplasia. Nevertheless, there is still much 
more to discover and describe. The more we know about mutations causing neoplasia, the 
better we get to know „the emperor of all maladies” - cancer. 
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